These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 19389564)

  • 21. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].
    Wolf SC; Buck-Müller N; Görner S; Risler T; Brehm BR
    Med Klin (Munich); 2003 Jan; 98(1):1-6. PubMed ID: 12540987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of nitric oxide release by nebivolol and its metabolites.
    Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
    Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
    Greven J; Gabriëls G
    Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A; Nuzum DS; Jolly JL
    Ann Pharmacother; 2006; 40(7-8):1353-60. PubMed ID: 16822893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart.
    Zhang ZS; Cheng HJ; Onishi K; Ohte N; Wannenburg T; Cheng CP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1203-11. PubMed ID: 16135702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure.
    de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):56-60. PubMed ID: 17666916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol.
    Parenti A; Filippi S; Amerini S; Granger HJ; Fazzini A; Ledda F
    J Pharmacol Exp Ther; 2000 Feb; 292(2):698-703. PubMed ID: 10640308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP; Giles TD; Sowers JR
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta.
    de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
    J Cardiovasc Pharmacol; 2003 Aug; 42(2):232-6. PubMed ID: 12883327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
    Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
    Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional beta3-adrenoceptor in the human heart.
    Gauthier C; Tavernier G; Charpentier F; Langin D; Le Marec H
    J Clin Invest; 1996 Jul; 98(2):556-62. PubMed ID: 8755668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
    Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
    Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors.
    Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
    Pharmacology; 2008; 81(2):110-7. PubMed ID: 17952013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of nebivolol on P wave duration and dispersion in patients with coronary slow flow.
    Güneş Y; Tuncer M; Güntekin U; Ceylan Y
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):290-5. PubMed ID: 19666430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring vascular benefits of endothelium-derived nitric oxide.
    Cockcroft JR
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
    Maack C; Böhm M; Vlaskin L; Dabew E; Lorenz K; Schäfers HJ; Lohse MJ; Engelhardt S
    Circulation; 2003 Jul; 108(3):348-53. PubMed ID: 12847069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.